Fig. 1

USP13 is highly amplified in NSCLC and associated with poor survival. A Genomic alteration frequency of USP13 gene in multiple cancer types. B Oncoprint mutation profile of KRAS, TP53, USP13, SOX2, and TP63 in LUSC (top) and LUAD (bottom). USP13, SOX2, and TP63 genes are co-amplified in NSCLC. C The correlation between mRNA expression and copy number variations (CNVs) of USP13 in LUSC (left) and LUAD (right). D Kaplan-Meier plots of NSCLC patients stratified by USP13 expression: Overall survival (top) and relapse-free survival (bottom) in LUSC (left) and LUAD (right). p-values were calculated using the log-rank test. E USP13 protein level in human LUSC. Representative IHC-staining images in a tissue microarray of adjacent normal tissue and LUSC (top) (scale bar, 200 µm). The red boxed areas on the left images were magnified and shown on the right. Relative USP13 protein levels in LUSC (n=75) and normal tissues (n=75) (bottom, left). USP13 expression levels in different LUSC grades (bottom, right). Grade 1 (n=5), grade 2 (n=50) and grade 3 (n=20). F USP13 protein level in human LUAD. Representative IHC-staining images in a tissue microarray of adjacent normal tissue and LUAD (top) (scale bar, 200 µm). The red boxed areas on the left images were magnified and shown on the right. Relative USP13 protein levels in LUAD (n=75) and normal tissues (n=75) (bottom left). USP13 expression levels in different LUAD grades (bottom, right). Grade 1 (n=11), grade 2 (n=45) and grade 3 (n=19). a.u., arbitrary unit. In (C), (E), and (F), boxes indicate the 10-90 percentile. Two-tailed unpaired t-tests, ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001